



Here is a selection of approved treatments for NETs:

Drug type	Drug name	Producer/partner	Target	Status
Somatostatin analogue	Sandostatin (octreotide) (generic competition)	Novartis	Somatostatin receptors	Approved 1998
Protein kinase inhibitor	Afinitor (everolimus)	Novartis	Mammalian target of rapamycin (mTOR)	Approved 2011
Radionuclide therapy for heochromocytoma	Azedra (iobenguane I-131)	Progenics Pharmaceuticals	Norepinephrine	Approved 2018
Radionuclide therapy for somatostatin positive NETs	Lutathera (lutetium Lu 177 dotatate)	Novartis/Fujifilm	Somatostatin receptors	Approved 2018
Somatostatin analogue	Somatuline Autogel (lanreotide)	Ipsen/Teijin	Somatostatin receptors	Approved 2014
VEGF inhibitor	Sutent (sunitinib)	Pfizer	VEGF receptor, FLT-3, platelet-derived growth factor receptor, KIT/c-KIT	Approved 2011
TPH inhibitor to reduce peripheral serotonin in carcinoid syndrome	Xermelo (telotristat)	Lexicon Pharmaceuticals	Tryptophan hydroxylase (TPH)	Approved 2017